Science

The drug development game needs a new playbook—one that prioritizes innovation over profit.

It's time we put researchers back in the driver’s seat.

Molecule is handing over the keys—giving researchers control over their research.

Welcome to the future of scientific funding👇

#DeSci biopharma IP tokenization protocol.


Fund research & shape early-stage research ideas on http://catalyst.molecule.xyz

As for researchers? Securing funding is a constant struggle.

They spend up to 40% of their time chasing grants. That’s not innovation, that’s bureaucracy.

We need a better way.

One that realigns incentives to support researchers and fund innovative science👇

With IP-NFTs and IP tokens (IPTs), researchers have a new way to turn intellectual property into an incentive for collaboration and funding.

Molecule turns IP into a tradable, shareable asset governed by the people who benefit most from the research.

IPTs level the playing field for researchers:

🔹 No need for early patents or startups to fundraise
🔹 Build a community of supporters
🔹 Keep control over your data and decide who gets access
🔹 Enable anyone to fund and benefit from your research

How do IP-NFTs work?

Think of it this way: IPNFTs own the core IP

🔹 IP can be held by a DAO, project, or researcher
🔹 Tokenized & tradable in liquid markets in the form of IPTs

How do IPTs work? 🧠

They are the fungible IP tokens of a project.

🔹 Governance tokens for an IP-NFT
🔹 They govern IP pools: shared sets of IP and R&D data
🔹 Multiple stakeholders can vote and control IP

Why is this important? 🔬

🔹 Enables open-source collaboration without losing commercial opportunity
🔹 Creates an arbitrage in biotech: more equity to patients & researchers = higher quality research at lower cost
🔹 Prioritizes effective cures over corporate profits

With IPTs, you’re not just backing research—you’re actively shaping its future.

IPTs are enabling a new drug discovery landscape. One with:

🔹 New incentive mechanisms
🔹 Democratized access to innovative research
🔹 Freedom from bureaucracy

So, how are IP-NFTs and IPTs being used?

🤝 BioDAOs like @vitadao, @valleydao, and @athenadao 
🌐 Catalyst
🧪 Pump Science

🤫 and more!

The future of drug discovery is decentralized. 🌐

And IPTs are just the beginning 🔭

To learn more about the impact of IP-NFTs and IPTs on the future of research funding, read more:

The future of drug discovery is decentralized. 🌐

And IPTs are just the beginning 🔭

To learn more about the impact of IP-NFTs and IPTs on the future of research funding, read more:
https://t.co/byykmghV4v

Right now, pharma:

❌ Prioritizes managing diseases over curing them
❌ Spends 25x more on promoting drugs than discovery
❌ Engage in ever-greening to extend patent protection

Innovation and progress struggle to thrive when all efforts focus on maintaining control.